Page last updated: 2024-12-11

n-desmethyltamoxifen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-desmethyltamoxifen: main metabolite of tamoxifen; RN given refers to (Z)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6378383
CHEMBL ID4525767
CHEBI ID80554
SCHEMBL ID2739189
MeSH IDM0092304

Synonyms (32)

Synonym
desmethyltamoxifen
ethanamine, 2-(4-(1,2-diphenyl-1-butenyl)phenoxy)-n-methyl-, (z)-
cis-2-(p-(1,2-diphenyl-1-butenyl)phenoxy)-n-methylethylamine
n-desmethyltamoxifen
ethylamine, 2-(p-(1,2-diphenyl-1-butenyl)phenoxy)-n-methyl-, (z)-
ici 55,548
31750-48-8
n-demethyltamoxifen
demethyltamoxifen
2-[4-[(z)-1,2-diphenylbut-1-enyl]phenoxy]-n-methylethanamine
unii-ooj759o35c
ooj759o35c ,
tamoxifen citrate impurity f [ep impurity]
2-(4-((z)-1,2-diphenylbut-1-enyl)phenoxy)-n-methylethanamine
ici-55548
desmethyltamoxifen, n-
ethanamine, 2-(4-((1z)-1,2-diphenyl-1-buten-1-yl)phenoxy)-n-methyl-
CHEBI:80554
SCHEMBL2739189
n-desmethyltamoxifen,hydrochloride
(2-{4-[(1z)-1,2-diphenylbut-1-en-1-yl]phenoxy}ethyl)(methyl)amine
NYDCDZSEEAUOHN-IZHYLOQSSA-N
n-desmethyl tamoxifen
(z)-2-(4-(1,2-diphenylbut-1-en-1-yl)phenoxy)-n-methylethanamine
n-desmethyltamoxifen, hydrochloride
Q27149597
2-[4-[(~{z})-1,2-diphenylbut-1-enyl]phenoxy]-~{n}-methyl-ethanamine
qbn ,
CHEMBL4525767
DTXSID501315924
(z)-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-n-methyl-ethanamine
AKOS040733807

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Results of the analysis showed that women who experienced at least one TAM-related side effect had significantly higher levels of TAM than women not experiencing any TAM-related side effects."( Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer.
Danton, M; Flaws, JA; Gallicchio, L; Lewis, LM; Lim, CK; Lord, G; Tkaczuk, K, 2004
)
0.32

Pharmacokinetics

ExcerptReferenceRelevance
" In addition, this study compiled pharmacokinetic parameters for the current 30 mg regimen in postmenopausal women, the target population of tamoxifen therapy."( Pharmacokinetics and bioavailability of tamoxifen in postmenopausal healthy women.
Fuchs, WS; Gay, S; Leary, WP; van der Meer, MJ; von Nieciecki, A; Witschital, K, 1996
)
0.29
" Pharmacokinetic and safety assessments were conducted throughout the trial."( A phase I study to determine the effect of tamoxifen on the pharmacokinetics of a single 250 mg oral dose of gefitinib (IRESSA) in healthy male volunteers.
Bailey, CJ; Cantarini, MV; Macpherson, MP; Marshall, AL; Robinson, AV, 2005
)
0.33
" The presence of tamoxifen did not have a clinically significant effect on the primary variables AUC and Cmax of gefitinib, nor on the secondary variables AUC(0-t), tmax, t1/2, and lambdaz."( A phase I study to determine the effect of tamoxifen on the pharmacokinetics of a single 250 mg oral dose of gefitinib (IRESSA) in healthy male volunteers.
Bailey, CJ; Cantarini, MV; Macpherson, MP; Marshall, AL; Robinson, AV, 2005
)
0.33
" Period 1, day 1, subjects were administered tamoxifen 40 mg followed by 23 days of blood sampling for pharmacokinetic analyses."( Open-label, 2-period sequential drug interaction study to evaluate the effect of a 100-mg dose of desvenlafaxine on the pharmacokinetics of tamoxifen when coadministered in healthy postmenopausal female subjects.
Braley, G; Liang, Y; Lubaczewski, S; Matschke, K; Nichols, AI; Ramey, T, 2014
)
0.4

Compound-Compound Interactions

ExcerptReferenceRelevance
" During period 2, subjects received desvenlafaxine 100 mg/d for 28 days; a single dose of tamoxifen 40 mg was administered with desvenlafaxine 100 mg on day 7, followed by 23 days of blood sampling."( Open-label, 2-period sequential drug interaction study to evaluate the effect of a 100-mg dose of desvenlafaxine on the pharmacokinetics of tamoxifen when coadministered in healthy postmenopausal female subjects.
Braley, G; Liang, Y; Lubaczewski, S; Matschke, K; Nichols, AI; Ramey, T, 2014
)
0.4
" Antidepressants (ADs), which are often coprescribed to patients receiving tamoxifen, are also metabolized by CYP2D6 and evidence suggests that a drug-drug interaction between these agents adversely affects the outcome of tamoxifen therapy by inhibiting endoxifen formation."( Application of Mice Humanized for CYP2D6 to the Study of Tamoxifen Metabolism and Drug-Drug Interaction with Antidepressants.
Henderson, CJ; MacLeod, AK; McLaughlin, LA; Wolf, CR, 2017
)
0.46

Bioavailability

ExcerptReferenceRelevance
"The bioavailability of two tamoxifen preparations (Tamoplex and Nolvadex) was compared in a multiple dose two-way cross-over design in twelve breast cancer patients."( The bioavailability of Tamoplex (tamoxifen). Part 3. A steady-state study in breast cancer patients.
Chapman, D; De Vos, D; Slee, PH; Stevenson, D, 1988
)
0.27

Dosage Studied

The major product co-eluted with one of the main peaks seen following treatment of rats with tamoxifen. We investigated concentrations of tamox ifen in serum, normal breast, and breast cancer tissues during conventional dosage and low-dose regimens.

ExcerptRelevanceReference
" Following dosing with N-desmethyltamoxifen, the major product co-eluted with one of the main peaks seen following treatment of rats with tamoxifen."( Further characterization of the DNA adducts formed in rat liver after the administration of tamoxifen, N-desmethyltamoxifen or N, N-didesmethyltamoxifen.
Brown, K; Heydon, RT; Jukes, R; Martin, EA; White, IN, 1999
)
0.83
" We investigated concentrations of tamoxifen, 4-hydroxytamoxifen, N-desmethyltamoxifen, and N-didesmethyltamoxifen in serum, normal breast, and breast cancer tissues during conventional dosage and two low-dose regimens."( Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial.
Decensi, A; Gjerde, J; Guerrieri-Gonzaga, A; Kisanga, ER; Lien, EA; Pelosi, G; Pesci-Feltri, A; Pigatto, F; Robertson, C; Serrano, D, 2004
)
0.56
" The drug is usually dosed 20 mg/d irrespective of interindividual variation in drug clearance."( Pronounced Interindividual But Not Intraindividual Variation in Tamoxifen and Metabolite Levels in Plasma During Adjuvant Treatment of Women With Early Breast Cancer.
Fotoohi, AK; Hatschek, T; Karim, H; Lafolie, P; Östervall, J; Pohanka, A; Vitols, S, 2016
)
0.43
"Large interindividual variation of tamoxifen and endoxifen with stable intraindividual levels, and too low levels of endoxifen in a considerable proportion of patients strongly support that therapeutic drug monitoring and individualized dosing could lead to optimal exposure and hopefully better outcome."( Pronounced Interindividual But Not Intraindividual Variation in Tamoxifen and Metabolite Levels in Plasma During Adjuvant Treatment of Women With Early Breast Cancer.
Fotoohi, AK; Hatschek, T; Karim, H; Lafolie, P; Östervall, J; Pohanka, A; Vitols, S, 2016
)
0.43
" There was little to no vaginal or systemic accumulation of tamoxifen following once-daily dosing for 28 days."( Vaginal tamoxifen for treatment of vulvar and vaginal atrophy: Pharmacokinetics and local tolerance in a rabbit model over 28 days.
Chollet, J; Friend, DR; Mermelstein, F; Rocamboli, SC, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
stilbenoidAny olefinic compound characterised by a 1,2-diphenylethylene backbone.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Tamoxifen Action Pathway1027
Tamoxifen Metabolism Pathway1027

Research

Studies (97)

TimeframeStudies, This Drug (%)All Drugs %
pre-199026 (26.80)18.7374
1990's21 (21.65)18.2507
2000's18 (18.56)29.6817
2010's24 (24.74)24.3611
2020's8 (8.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.22 (24.57)
Research Supply Index4.73 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (7.69%)5.53%
Reviews4 (3.85%)6.00%
Case Studies1 (0.96%)4.05%
Observational0 (0.00%)0.25%
Other91 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]